Kovcs R, Schuchmann S, Gabriel S, Kann O, Kardos J, Heinemann U
In the U.S., post-market surveillance data from 20052023 show over 6,700 cases of pancreatitis tied to GLP-1 drugs, leading to growing concern among healthcare providers and attorneys
[1] Important safety considerations include the risk of hypoglycaemia when combined with insulin or sulfonylureas, potential dehydration and acute kidney injury with severe gastrointestinal symptoms, and for semaglutide specifically, possible worsening of diabetic retinopathy in those with pre-existing disease
En 2014, la FDA aprob el frmaco GLP-1 para la diabetes de tipo 2 Victoza (liraglutida) para tratar la obesidad bajo una marca diferente, Saxenda
Following administration, Modified GRF(1-29) produces peak effects within 15-30 minutes, with duration of elevated GH typically lasting 2-3 hours based on GHRH analog pharmacology
For those over age 75, there were more hip fractures (1.3% vs